I agree. Comparing or lumping Ocata in with other start up biotech companies is not logical. The fear was that RPE would not engraft and would cause a tumor(s), and would not be safe and would not improve eye sight. These are all like on/off switch type success/failure results. We have only seen the on switch as far as results. If they work they work, Kind of like chocolate on Valentines day.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.